PDF(Pubmed)
Abstract：
As solid organ transplant (SOT) recipients remain at risk of severe outcomes after SARS-CoV-2 infections, vaccination continues to be an important preventive measure. In SOT recipients previously vaccinated with at least three doses of BNT162b2, we investigated humoral responses to BNT162b2 booster doses. Anti-SARS-CoV-2 receptor binding domain (RBD) immunoglobulin G (IgG) was measured using an in-house ELISA. Linear mixed models were fitted to investigate the change in the geometric mean concentration (GMC) of anti-SARS-CoV-2 RBD IgG after vaccination in participants with intervals of more or less than six months between the last two doses of vaccine. We included 107 SOT recipients vaccinated with a BNT162b2 vaccine. In participants with an interval of more than six months between the last two vaccine doses, we found a 1.34-fold change in GMC per month (95% CI 1.25-1.44), while we found a 1.09-fold change in GMC per month (95% CI 0.89-1.34) in participants with an interval of less than six months between the last two vaccine doses, resulting in a rate ratio of 0.82 (95% CI 0.66 to 1.01, p = 0.063). In conclusion, the administration of identical COVID-19 mRNA vaccine boosters within six months to SOT recipients may result in limited humoral immunogenicity of the last dose.
摘要：
由于实体器官移植（SOT）受者在SARS-CoV-2感染后仍面临严重结局的风险，疫苗接种仍然是一项重要的预防措施。在先前接种至少三剂BNT162b2疫苗的SOT接受者中，我们研究了对BNT162b2加强剂量的体液反应。使用内部ELISA测量抗SARS-CoV-2受体结合结构域(RBD)免疫球蛋白G(IgG)。拟合线性混合模型，以研究参与者接种疫苗后抗SARS-CoV-2RBDIgG的几何平均浓度（GMC）的变化，最后两剂疫苗之间的间隔大于或小于六个月。我们包括107例接种BNT162b2疫苗的SOT接受者。在最后两次疫苗剂量之间间隔超过六个月的参与者中，我们发现GMC每月变化1.34倍(95%CI1.25-1.44)，虽然我们发现参与者的GMC每月变化1.09倍（95％CI0.89-1.34），最后两次疫苗剂量之间的间隔不到六个月，导致比率为0.82（95%CI0.66至1.01，p=0.063）。总之,在6个月内向SOT接受者施用相同的COVID-19mRNA疫苗增强剂可能导致最后一次剂量的体液免疫原性有限。
